姓名：周红刚
职称：教授，博导
职务：药学院院长助理/转化中心主任/仪器平台主任
学科方向：分子药理学
招生方向：分子与细胞生物学，临床免疫与药理学，生物工程与制药学
通讯地址：天津市津南区海河教育园同砚路38号南开大学药学院，300350
电话：022-85358566
电子邮件：honggang.zhou@nankai.edu.cn
【个人简介】
2010毕业于英国雷丁大学（University of Reading, UK）药学院药理专业，获博士学位；2011年入职南开大学药学院任讲师；2015年晋升为副教授；2022年晋升为教授，2023年评为博导。主要研究方向为器官炎症/纤维化的新靶点、新机制及创新药物研发，包括化药/改良型化药，生物药、中药院内制剂开发。课题组基于对临床需求的理解、对发病机制的探索以及对靶点、药理的创新和认知，从事机制研究与新药转化工作。主持“国自然基金”3项、主持“天津市科技重大专项”1项；作为骨干参与“国家重大专项”2项，天津市科技重大专项与工程1项；主持承担企业横向课题22项（纵向和横向课题合计到账金额为1800余万元）。作为主要研究者进行了多个1类新药临床前研究，获批新药临床批件4件（包括南开大学首个临床批件证书）。共申报发明专利144项，获得授权52项；共发表文章153篇，包括在Science Advances，Molecular Therapy，Signal Transduction and Targeted Therapy杂志上发表SCI文章123篇，h-index为32。担任“Journal of Advanced Research”、“ Bioengineered”、“Biochemical Pharmacology”等33个期刊审稿人。担任 “天津市中药传承创新发展专家委员会”委员；“中国研究型医院学会呼吸病学专业委员会间质性肺病多学科诊治(ILD-MDD)专家委员会”委员； “天津市药理学会呼吸与危重症医学专业委员会”第一届委员；“天津市医疗健康学会呼吸疾病专业委员会”委员等。
入选了天津市“用三年时间引进千名以上高层次人才”和“滨海新区天津市131创新型第二层次”人才称号。连续四年指导研究生获得国家奖学金和南开大学一等奖学金，2021年获“南开大学优秀硕士学位论文指导教师”称号。指导大学生创新创业大赛，共获国家/天津市/校级奖共计30余次，其中获国家铜奖2次，天津市各奖项12次，2020年获“南开大学创新创业优秀指导教师”称号，2024年获“新民药学优秀教师奖”。
【主要研究方向】
1. 聚焦疾病方向：肺间质病、器官纤维化（肾、皮肤、心脏、肝纤维化，后发性白内障）、免疫炎症疾病
2. 疾病创新靶点机制研究及基于临床需求的创新药物研发：抗体药物（单克隆当体、抗体偶联药物ADC），小分子化药，小核酸药物
3. 中药院内制剂研发及创新药转化研究
4. 创新药物的体内外药物代谢与药物动力学研究
5. 药物新剂型在治疗呼吸系统疾病的应用
【在研课题】（有硕士名额，欢迎同学们咨询）
一、抗肺纤维化药物研发及特发性肺纤维化致病机制研究
1. 创新化药和生物药（单克隆抗体、抗体偶联药物、多肽和核酸药物）在肺纤维化的作用机制研究与药物开发
2. 针对特发性肺纤维化 1类新药CP0116的机制机理与临床前研究（国家十三五重大新药创制科技重大专项“治疗特发性肺纤维化创新药物的研发”）
3. 特发性肺纤维化以及自身免疫性疾病引起肺间质病的潜在创新靶点作用机制研究（国家自然科学基金面上项目）
4. “上市药物再开发”与中药单体治疗肺纤维化作用药效和机制研究
5. 特发性肺纤维化急性加重（AE-IPF）及肺间质病合并症的相关新药研发
二、器官纤维化筛选评价体系构建及活性先导化合物成药性评价
1. 器官纤维化筛选评价体系构建及活性先导化合物成药性评价（天津市科技计划项目“肺纤维化药物研发平台建设”）
2. 肾脏纤维化/慢性肾病疾病机制研究及药物研发
3. 皮肤纤维化类瘢痕增生疾病药物筛选体系建立及治疗药物研发
4. 心脏纤维化高通量药物筛选体系建立及治疗药物研发
5. 后发性白内障（眼睛纤维化）新药开发以及药效及药理作用研究
6. 肝脏纤维化和NASH新药开发以及药效及药理作用研究
三、呼吸系统、免疫炎症和代谢相关疾病评价体系构建及活性先导化合物成药性评价
1. 结缔组织疾病相关间质性肺疾病（CTD-ILD）药物筛选体系建立及先导化合物成药性评价
2. 急性肺损伤筛选评价体系构建及活性先导化合物成药性评价
3. 免疫炎症疾病高通量细胞筛选评价体系构建及活性先导化合物成药性评价
4. 消化系统疾病动物模型（炎性肠病IBD为主）药物开发以及机制机理研究
5. 银屑病动物模型建立及优势化合物筛选
6. 脓毒症动物模型建立及优势化合物筛选
【近期论文发表情况】
1. Jingyan Zhu§, Qiuyan Jiang§, Shaoyan Gao§, Qin Xia, Huizhe Zhang, Bowen Liu, Ruixi Zhao, Haixia Jiang, Xiaohe Li, Aiguo Xu,*, Honggang Zhou,**, Zuojun Xu,*, Cheng Yang,**. IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation. Pharmacological Research, 2024.
2. Ruiqin Zhang§, Qiuyan Jiang§, Shaoyan Gao§, Huizhe Zhang, Qin Xia, Bowen Liu, Jingyan Zhu, Haixia Jiang, Ruixi Zhao, Huixuan Dong, Xiaohe Li, Yanping Zhang, Cheng Yang, Xiaoting Gu, Liang Sun, Honggang Zhou*. Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization. International Immunopharmacology, 2024.
3. Bowen Liu§, Qiuyan Jiang§, Ruxuan Chen§, Huizhe Zhang, Qin Xia, Chi Shao, Xiangning Liu, Mengqi Wang, Yujie Shi, Jingyan Zhu, Ruixi Zhao, Haixia Jiang, Shaoyan Gao, Xiaohe Li, Honggang Zhou*, Cheng Yang*, Hui Huang,*. Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes. International Immunopharmacology, 2024.
4. Shimeng Li§, Zhichao Liu§, Xiaodan Jiao§, Jinying Gu§, Zhigang Liu, Lingxin Meng, Wenqi Li, Tiantian Zhang, Jing Liu, Dan Chai, Jiaai Liu, Zhongyi Yang, Yuming Liu, Ran Jiao, Xiaohe Li*, Honggang Zhou*, Yanping Zhang*. Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. Biochemical Pharmacology，2024.
5. Yuming Liu§, Zhigang Liu§, Xiaohe Li§, Wenqi Li, Zhongyi Yang, Ran Jiao, Qing Wang, Lingxin Meng, Tiantian Zhang, Jing Liu, Dan Chai, Na Zhang*, Shouchun Peng*, Honggang Zhou* and Cheng Yang*. Nerandomilast improves bleomycin-induced systemic sclerosis-associated interstitial lung disease in mice by regulating the TGF-β1 pathway. Inflammation，2024.
6. Jianwei Zhang§, Xiujun Zhang§, Xiaowei Guo§, Wenqi Li§, Tiantian Zhang, Dan Chai, Yuming Liu, Li Chen, Xiaoyu Ai, Tianyuan Zhou, Wenguo Wei*, Xiaoting Gu*, Xiaohe Li*, Honggang Zhou*. Remdesivir alleviates skin fibrosis by suppressing TGF-β1 signaling pathway. Plos one，2024.
7. Hailong Li§, Jinhe Li§, Yayue Hu§, Ruotong Zhang, Xiaoting Gu, Yiying Wei, Shanshan Zhang, Xuefen Chen, Luqing Wei, Xiaohe Li, Songtao Gu, Jin Jin, Hui Huang*, Honggang Zhou*, Cheng Yang*. FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary fibrosis. International Journal of Biological Sciences, 2023.
8. Ting Xiao§, Dandi Gao§, Xiaoting Gu§, Yanping Zhang§, Yuxin Zhu, Zihui Zhang, Yiming He, Luqing Wec, Hongli Li*, Honggang Zhou*, Cheng Yang*. Flavokawain Aameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axis. European Journal of Pharmacology, 2023.
9. Ting Xiao§, Jiali Bao§, Jiao Tian§, Rong Lin, Zihui Zhang, Yuxin Zhu, Yiming He, Dandi Gao, Ronghao Sun, Fubo Zhang, Yexin Cheng, Jiadelati Shaletanati, Honggang Zhou*, Chunfeng Xie*, Cheng Yang*. Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT. Phytomedicine, 2023
10. Xiaohe Li§, Xiaoyang Ma§, Yang Miao§, Jianwei Zhang, Buri Xi, Wenqi Li, Qianyi Zhang, Li Chen, Yue Yang, Hongli Li, Luqing Wei,* Honggang Zhou,* Cheng Yang*. Duvelisib Attenuates Bleomycin-Induced Pulmonary Fibrosis via Inhibiting the PI3K/Akt/mTOR Signaling Pathway. Journal of Cellular and Molecular Medicine, 2023.
11. Hailong Li§, Ruotong Zhang§, Yayue Hu§, Jinhe Li, Ying Yang, Dan Wu, Xiaoting Gu, Fubo Zhang*, Honggang Zhou*, Cheng Yang*. Axitinib attenuates the progression of liver fibrosis by restoring mitochondrial function. International Immunopharmacology, 2023.
12. Ting Xiao§, Shanfa Ren§, Jiali Bao§, Dandi Gao, Ronghao Sun, Xiaoting Gu, Jingjing Gao, Shanshan Chen, Jin Jin, Luqing Wei, Chunwa Wu, Cheng Yang*, Guang Yang*, Honggang Zhou*. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study. European Journal of Pharmacology, 2023.
13. Yang Miao, Yanhua Wang, Zhun Bi, Kai Huang, Jingjing Gao, Xiaohe Li, Shimeng Li1, Luqing Wei*, Honggang Zhou* and Cheng Yang*. Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine, 2023.
14. Shaoyan Gao§, Xiaohe Li§, Qiuyan Jiang§, Qing Liang, Fangxia Zhang, Shuangling Li, Ruiqin Zhang, Jiaoyan Luan, Jingyan Zhu, Xiaoting Gu, Ting Xiao, Hui Huang, Shanshan Chen, Wen Ning*, Guang Yang*, Cheng Yang*, Honggang Zhou*. PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling. Science Advances, 2022.
15. Shanshan Chen,§ Yuli Wei,§ Shimeng Li,§ Yang Miao,§ Jinying Gu, Yunyao Cui, Zhichao Liu, Jingjing Liang, Luqing Wei, Xiaohe Li,* Honggang Zhou,* Cheng Yang, *. Zanubrutinib Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway.International Immunopharmacology, 2022.
16. Bowen Liu§, Qiuyan Jiang§, Ruxuan Chen§, Shaoyan Gao, Qin Xia, Jingyan Zhu, Fangxia Zhang, Chi Shao, Xiangning Liu, Xiaohe Li, Honggang Zhou, * Cheng Yang, * Hui Huang*. Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling. International Immunopharmacology, 2022.
17. Hailong Li§, Jinhe Li§, Ting Xiao§, Yayue Hu, Ying Yang, Xiaoting Gu, Ge Jin, Hailong Cao*, Honggang Zhou* and Cheng Yang. Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers in Pharmacology, 2022.
18. Kun Zhang§, Jingjing Liang§, Ning Wang, Ning Li, Yurui Jiang, Xiaohe Li*, Cheng Yang*, Honggang Zhou*, Guang Yang*. Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay. European Journal of Medicinal Chemistry, 2022.
19. Xiaohe Li§, Yuli Wei§, Shimeng Li§, Jingjing Liang, Zhichao Liu, Yunyao Cui, Jingjing Gao, Zhongyi Yang, Lei Li, Honggang Zhou*, Shanshan Chen*, Cheng Yang*. Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.International Immunopharmacology, 2022.
20. Hai-long Li§, Yi-ying Wei§, Xiao-he Li§, Shan-shan Zhang, Ruo-tong Zhang, Jin-he Li, Bo-wei Ma, Shuai-bo Shao, Zi-wei Lv, Hao Ruan, Honggang Zhou* and Cheng Yang. Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis. Acta Pharmacologica Sinica，2022.
21. Ting Xiao§, Shanfa Ren§, Jiali Bao§, Dandi Gao, Ronghao Sun, Xiaoting Gu, Jingjing Gao, Shanshan Chen, Jin Jin, Luqing Wei, Chunwa Wu, Cheng Yang*, Guang Yang*, Honggang Zhou*. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STA1/3 signaling pathway-an experimental in vitro and vivo study. European Journal of Pharmacology, 2022
22. Ming Wang§, Shanfa Ren§, Zhun Bi§, Liang Zhang, Mengqi Cui, Ronghao Sun, Jiali Bao, Dandi Gao, Bo Yang, Xiaoping Li, Mingjiang Li, Ting Xiao*, Honggang Zhou*, Cheng Yang. Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1. Phytotherapy Research, 2022.
23. Ting Xiao§, Mengqi Cui§, Caijuan Zheng§, Peipei Zhang, Shanfa Ren, Jiali Bao, Dandi Gao, Ronghao Sun, Ming Wang, Jianping Lin, Liang Zhang, Mingjiang Li, Dongmei Li*, Honggang Zhou* and Cheng Yang*. Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS‐CoV‐2 Replication by Targeting Mpro and Sepsis in Mice, Inflammation, 2022.
24. Xiaohe Li§, Qing Liang§, Shaoyan Gao§, Qiuyan Jiang§, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou*, Hui Huang*, Cheng Yang*. Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. International Immunopharmacology，2022.
25. Ruotong Zhang§, Yiying Wei§, Shanshan Zhang§, Hailong Li§, Jinhe Li, Bowei Ma, Xiaoqing Zhu, Xudong Song*, Honggang Zhou*. Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups. Current Eye Research，2022.
26. Bo Yang§, Ling Ma§, Yuli Wei§, Yunyao Cui, Xiaohe Li, Yiying Wei, Shanshan Zhang, Liang Zhang, Honggang Zhou*, Guangshun Wang*, Xiaoping Li*. Isorhamnetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting mTOR signaling pathway. Immunopharmacol Immunotoxicol, 2022.
27. 刘智超，李霄鹤，周红刚，张娜*.特发性炎性肌病相关间质性肺疾病动物模型概述. 天津医药，2024.
28. 陈莉，朱婧妍，高劭妍，谷小婷，李霄鹤*，周红刚*. 尼达尼布治疗间质性肺疾病的作用机制研究进展. 中国药理学通报，2023.
29. 陈莉，朱雨昕，李霄鹤，肖婷，谷小婷*，周红刚*. 瘢痕疙瘩细胞和分子机制研究进展. 中国药理学通报，2023.
30. 肖婷，暴嘉丽，刘湘宁，黄慧*，周红刚*. 特发性肺纤维化合并非小细胞肺癌的致病机制及潜在治疗药物研究进展. 中国肺癌杂志，2022.
31. 卫怡颖，马博威，李海龙，宋旭东*，周红刚*. 中药单体治疗白内障的研究进展. 中国老年学杂志，2022.
32. 李海龙，张若彤，卫怡颖，张杉杉，马博威，李霄鹤*，周红刚*. 环状 RNA 在肺纤维化中的作用研究进展. 中国药理学与毒理学杂志，2022.
33. 张杉杉，李海龙，李晓平，李霄鹤*，周红刚*. 酪氨酸激酶抑制剂与器官纤维化研究进展. 中国药学杂志，2022.